Veterinary

Mountain Valley MD Provides Business Update, Appoints New CFO

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health, Pharmaceutical, Vitamins, Supplements, Agriculture, Natural Resources, Research, Fitness & Nutrition, Environment, Science, Veterinary, Deep Sleep, Animal, Growth, Commerce, Sale, Powder, Climate change, HLB, Eon, Farm, MVDM, Livestock, McGill University, Micronutrient, Plant, GMP, Tree, Eons.com, Nutraceutical, Immunity, Tablet, Photosynthesis, CW, CPA, FRA, Sleep, Calendar, Tilapia, Logic, Catfish, CFO, Ivermectin, Aquaculture, Fishery, Patent, Consultant, Biomass, Government, Licensee, Nutrient, Republic, Cognition, Citrus, Disease

The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.

Key Points: 
  • The MVMD team and our extensive network of partners has made significant progress advancing our commercialization priorities,” stated Dennis Hancock, President & CEO of Mountain Valley MD.
  • To date, the Company has worked on a range of formulations for Quicksome™-powered product applications, including sleep, energy, appetite suppressant, cognition, immunity, calm, and pain relief.
  • The Company believes this will be valuable in its business development efforts and broad growth plans for its nutraceutical line of business.
  • Since July 2009, his tenure at Malaspina Consultants Inc. has been marked by CFO and accounting roles for various public and private companies across multiple industries.

AI-Powered, Plant-Based Dog Food Brand PawCo Raises $2M to Scale Its Operations

Retrieved on: 
Thursday, February 29, 2024
Veterinary, Pets, Health, Artificial Intelligence, Technology, Food, Beverage, Consumer, Retail, Pet, Cancer, Dicarboxylic acid, AI, Impossible Foods, Marketing, Mineral, Vitamin, Growth, Dog, Meat, Allergy, Research, Environment

With this funding, PawCo will scale its operations by opening a second production facility (a midwest location to complement its current facility in California).

Key Points: 
  • With this funding, PawCo will scale its operations by opening a second production facility (a midwest location to complement its current facility in California).
  • Additionally, the brand will further invest in growth, research and development, new recipes and marketing tactics to drive awareness for the plant-based pet food category.
  • PawCo offers a plant-based meat alternative that provides all the essential vitamins, minerals, and amino acids dogs need to thrive, without sacrificing taste and flavor.
  • To learn more about PawCo, please visit mypawco.com .

Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference

Retrieved on: 
Thursday, February 29, 2024
Health, Agriculture, Natural Resources, General Health, Vitamins, Supplements, Biotechnology, Veterinary, PAHC, Conference

Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference.
  • Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Tuesday, March 12, 2024, at 4:35 PM ET at the Loews Miami Beach Hotel.
  • The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com .
  • A replay of the session will be available and archived on the company’s website.

CityVet Lands a Spot on Inc. Magazine’s List of the Southwest Region’s Fastest-Growing Private Companies

Retrieved on: 
Thursday, February 29, 2024
Health, Veterinary, Pets, Consumer, Pet, Database, Growth, Regionals, Multimedia, Airline

123 on its fourth annual Inc. 5000 Regionals: Southwest list, the most prestigious ranking of the fastest-growing Southwest private companies, based in Arizona, New Mexico, Oklahoma, and Texas.

Key Points: 
  • 123 on its fourth annual Inc. 5000 Regionals: Southwest list, the most prestigious ranking of the fastest-growing Southwest private companies, based in Arizona, New Mexico, Oklahoma, and Texas.
  • Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Southwest economy’s most dynamic segment–its independent small businesses.
  • (Photo: Business Wire)
    On receiving the recognition, CityVet CEO David Boguslawski says, “We are honored to be recognized by Inc. as one of the fastest-growing private companies in the Southwest.
  • The companies on this list show a remarkable rate of growth across all industries in the Southwest region.

Chewy Announces Fiscal Fourth Quarter and Full Year 2023 Financial Results Conference Call

Retrieved on: 
Wednesday, February 28, 2024
Retail, Health, Consumer, Other Retail, Specialty, Pets, Veterinary, CHWY, PIN, Chewy

Chewy, Inc. (NYSE: CHWY) (“Chewy”), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal fourth quarter and full year 2023 financial results after the market close on Wednesday, March 20, 2024.

Key Points: 
  • Chewy, Inc. (NYSE: CHWY) (“Chewy”), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal fourth quarter and full year 2023 financial results after the market close on Wednesday, March 20, 2024.
  • Management will host a conference call and webcast to discuss the company's financial results at 5:00 pm ET.
  • To access the conference call by phone, please visit this link for registration ( Phone Registration Link ) to be provided with dial in details, including a unique PIN to access the conference call.
  • To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call.

Patterson Companies Reports Fiscal 2024 Third Quarter Operating Results

Retrieved on: 
Wednesday, February 28, 2024
Medical Supplies, Health, Dental, General Health, Pharmaceutical, Veterinary, Acquisition, Collection, Share repurchase, Growth, Disclosure, Risk, Conference, GAAP, Consolidated, Tax, Public expenditure, Animal Health, Instrument, Patterson Companies, Internal, Public, Security (finance)

Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2024 third quarter ended January 27, 2024.

Key Points: 
  • Patterson Companies, Inc. (Nasdaq: PDCO) today reported operating results for its fiscal 2024 third quarter ended January 27, 2024.
  • Reported net income attributable to Patterson Companies, Inc. for the third quarter of fiscal 2024 was $47.7 million, or $0.52 per diluted share, compared to $53.9 million, or $0.55 per diluted share, in the third quarter of fiscal 2023.
  • Adjusted net income1 attributable to Patterson Companies, Inc., which excludes deal amortization, totaled $55.0 million for the third quarter of fiscal 2024, or $0.59 per diluted share, compared to $61.1 million, or $0.62 per diluted share, in the third quarter of fiscal 2023.
  • Patterson Companies’ fiscal 2024 third quarter conference call will start at 8:30 a.m. Eastern today.

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024
Veterinary, Research, Pets, Clinical Trials, Biotechnology, Health, Consumer, General Health, Science, Pet, Doctor of Philosophy, Dementia, Quality of life, Ageing, Animal, Dog, Neurology, NCSU, Gene expression, Happiness, Cognition, Clinical trial, Frailty, Harvard Medical School, Genetics, BioRxiv, Human, Pharmaceutical industry

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Veterinary, MERS, Dengue fever, Atopic dermatitis, Kinetics, RBD, Vaccination, Immunoglobulin G, Chronic pain, Nerve growth factor, Dementia, Protein, Infection, CGMP, Notifiable disease, Immune system, Vaccine

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

PhenoSys Now Offers Turnkey Mini2P Systems with poLight ASA Tunable Optics

Retrieved on: 
Wednesday, February 21, 2024
Hardware, Manufacturing, Photography, Technology, Nanotechnology, University, Audio, Video, Education, Neurology, Biotechnology, Science, Software, Veterinary, Research, Health, Engineering, Nobel Prize, Moser research environment, PLT, Systems neuroscience, ASA, Kavli, Dementia, DAQ, Brain

poLight ASA (OSE: PLT) today announced that PhenoSys , a leader in engineering and market innovative technology for animal behaviour research, offers a Mini2P turnkey solution that includes TLens® for optimal microscopic imaging.

Key Points: 
  • poLight ASA (OSE: PLT) today announced that PhenoSys , a leader in engineering and market innovative technology for animal behaviour research, offers a Mini2P turnkey solution that includes TLens® for optimal microscopic imaging.
  • The PhenoSys system includes the miniature two-photon (Mini2P) microscope body for X-Y-Z plane scanning, fiber optics and cabling, two-photon laser, detection unit, flexible DAQ hardware and software, and full technical support.
  • Mini2P is an open-source miniature two-photon microscope brain explorer developed by Kavli Institute for Systems Neuroscience at Norwegian University of Science and Technology.
  • “We are excited to see commercial players suppling the tools and resources to accelerate deployment of Mini2P systems.

Pet Honesty® Introduces Groundbreaking Restore + Soothe Line, Elevating Pet Skincare with MicroSilver BG™ Innovation

Retrieved on: 
Wednesday, February 21, 2024
Veterinary, Other Retail, Pets, Specialty, Health, Cosmetics, Consumer, Retail, Online Retail, Restore, Bacteria, Oil, Dog, Soothe, Paraben, Skin, Veterinarian, Skin care, Research and development, Sulfate, Vaccine

Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.

Key Points: 
  • Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.
  • At the core of the Restore + Soothe line is MicroSilver BG™, a clinically studied ingredient crafted from pure, elemental silver.
  • Greg Reinhart, Ph.D, Vice President of Research & Development at Pet Honesty, expressed enthusiasm for MicroSilver BG™, stating, “MicroSilver BG™ is a game-changer in pet skincare.
  • The Restore + Soothe Spray ($14.99) offers fast relief in a natural formulation, and the Restore + Soothe Ear Cleaner ($19.99) provides quick relief for ear issues.